Vascular Access Closure Ten Years Later: Why Start-Ups Can't Seal the Deal

Despite the best intentions and brightest innovation, start-ups haven't been able to tap into the huge potential presented by the vascular closure market. Ten years after the first generation devices made it to market, the original two leaders still dominate despite the limitations of their devices, while many start-ups have come and gone. A long list of new hopefuls believe they have the solution physicians have desired. Now all they have to do is convince the physicians, who, when it comes to vascular closure devices, are slow to recognize clinical data but quick to embrace a device that feels right to them.

Mary Stuart

The more things change, the more they remain the same. Looking back at the article on vascular access closure devices that we wrote in May 2004, it’s amazing how many of the devices—and the companies themselves--have simply disappeared. (See "An Open Market for Vascular Access Closure Devices," START-UP, May 2004 Also see "An Open Market for Vascular Access Closure Devices " - Medtech Insight, 1 May, 2004..) Of the survivors, only two are making headway in the market—AccessClosure Inc. and Cardiva Medical Inc.—and they’re going up against the same leaders: St. Jude Medical Inc. with Angio-Seal and Abbott Laboratories Inc. with Perclose and StarClose. St

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight